Compare · DFTX vs MDWD
DFTX vs MDWD
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and MediWound Ltd. (MDWD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and MDWD operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $4.60B, about 29.2x MDWD ($157.6M).
- DFTX has been more active in the news (11 items in the past 4 weeks vs 1 for MDWD).
- Both have 8 recent analyst ratings on file.
- Company
- Definium Therapeutics Inc.
- MediWound Ltd.
- Price
- -
- -
- Market cap
- $4.60B
- $157.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- News (4w)
- 11
- 1
- Recent ratings
- 8
- 8
MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Latest DFTX
- Definium Therapeutics Announces New Employee Inducement Grants
- Analyst initiated coverage on Definium Therapeutics with a new price target
- Chief Medical Officer Karlin Daniel sold $396,894 worth of shares (10,853 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 792,846 units (SEC Form 4) (withholding obligation)
- Chief Executive Officer Barrow Robert sold $1,153,784 worth of shares (31,550 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 2,213,090 units (SEC Form 4) (for withholding tax)
- Chief Commercial Officer Wiley Matthew T. sold $113,257 worth of shares (3,097 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.86% to 359,036 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Sullivan Mark sold $513,845 worth of shares (14,051 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 494,228 units (SEC Form 4) to satisfy withholding tax
- Chief Financial Officer Roberts Brandi sold $123,497 worth of shares (3,377 units at $36.57) as part of a pre-agreed trading plan, decreasing direct ownership by 0.85% to 394,528 units (SEC Form 4) (withholding tax)
- Definium Therapeutics Announces New Employee Inducement Grants
- SEC Form 144 filed by Definium Therapeutics Inc.
- SEC Form 144 filed by Definium Therapeutics Inc.
Latest MDWD
- MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
- Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
- Director Rubinstein Samuel sold $6,678 worth of Ordinary Shares (525 units at $12.72) and bought $6,626 worth of Ordinary Shares (525 units at $12.62) (SEC Form 4)
- MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- COO & Chief Commercial Officer Hess Shmuel sold $75,394 worth of Ordinary Shares (5,823 units at $12.95), closing all direct ownership in the company (SEC Form 4)
- SEC Form 6-K filed by MediWound Ltd.
- MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- MediWound to Report Second Quarter 2026 Financial Results
- Director Shamir Nachum bought $83,996 worth of Ordinary Shares (6,000 units at $14.00), increasing direct ownership by 12% to 55,815 units (SEC Form 4)
- Director Fox David Morton bought $49,901 worth of Ordinary Shares (3,537 units at $14.11), increasing direct ownership by 19% to 22,283 units (SEC Form 4)